Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit-Reference-Cited by-同舟云学术

Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit

Published:2017-05 Issue:3 Volume:11 Page:602-616
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Hovingh G. Kees,Goldberg Anne C.,Moriarty Patrick M.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference73 articles.

1. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS);Aengevaeren;J Am Coll Cardiol,1996

2. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation;Alonso;J Am Coll Cardiol,2014

3. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis;Barter;Arterioscler Thromb Vasc Biol,2003

4. Effects of torcetrapib in patients at high risk for coronary events;Barter;N Engl J Med,2007

5. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence?;Barter;Clin Ther,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The genetics of autosomal dominant familial hypercholesterolemia;Journal of the American Association of Nurse Practitioners;2023-08-25

2. Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition;Clinica Chimica Acta;2023-01

3. Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study;Arteriosclerosis, Thrombosis, and Vascular Biology;2022-12

4. Clinical implications and outcomes of the ORION Phase III trials;Future Cardiology;2021-08

5. Evinacumab for treatment of familial hypercholesterolemia;Expert Review of Cardiovascular Therapy;2021-07-22